Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20000697 | 1.00 | REN (0.82) | REN | |
| SCHEMBL17812896 | 1.00 | REN (0.82) | REN | |
| SCHEMBL13486098 | 1.00 | REN (0.82) | REN | |
| SCHEMBL13906294 | 0.95 | REN (0.81) | REN | |
| SCHEMBL7379865 | 0.94 | REN (0.83) | REN | |
| SCHEMBL7545740 | 0.92 | REN (0.82) | REN | |
| SCHEMBL14190816 | 0.92 | REN (0.82) | REN | |
| SCHEMBL12957327 | 0.91 | REN (0.78) | REN | |
| SCHEMBL881010 | 0.91 | REN (0.80) | REN | |
| SCHEMBL1941950 | 0.90 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-3544966-B1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-08-08 | — | — | US | disclosed |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9982017-B2 | Synthetic apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-05-29 | — | — | US | disclosed |
| US-9931372-B2 | Synthetic apelin fatty acid conjugates with improved half-life | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116435-A2 | METHODS OF TREATING ATHEROSCLEROSIS | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006078606-A2 | ATI RECEPTOR ANTAGONISTS FOR TREATING VASCULAR INFLAMMATION | NOVARTIS AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006041974-A1 | USE OF RENIN INHIBITORS FOR THE PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041763-A1 | RENIN INHIBITORS FOR TREATING TRANSPLANTATION INDUCED DISEASES | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006029349-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005089731-A2 | USE OF RENIN INHIBITORS IN THERAPY | NOVARTIS AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2003099279-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | REN 40/4885 |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | REN 24/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | REN 24/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | REN 19/4885 |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | REN 2/4885 |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | MME, REN, ECE1 | REN 2/4885 |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | APLNR, AP3B1, FABP3 | REN 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.